Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Doximity: Slowing Sales And EBITDA Growth
Doximity shares have dropped nearly 25% from February highs, despite strong Q4 earnings and 17% revenue growth year-over-year. Analyst sentiment is mixed, and insider selling has notably increased in 2025. Doximity boasts a robust balance sheet with $915 million in cash, no long-term debt, and an impressive rise in free cash flow in its last reported quarter.
Doximity (DOCS) Upgraded to Strong Buy: Here's Why
Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Doximity (DOCS) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Doximity (DOCS) stood at $59.38, denoting a -1.44% move from the preceding trading day.
Doximity (DOCS) Rises Higher Than Market: Key Facts
Doximity (DOCS) concluded the recent trading session at $61.55, signifying a +2.24% move from its prior day's close.
Dr Martens tiptoes higher after positive America retail trading, UK still challenging
Dr Martens PLC (LSE:DOCS) said trading since the start of the financial year has been in line with expectations, with guidance for its current financial year unchanged and profit expected to be weighted to the second half The FTSE 250-listed footwear manufacturer and retailer reported a "positive" performance for its direct-to-consumer business in the Americas, particularly in its shops and full-price sales, though the UK continued to see "a challenging trading backdrop". In Europe, the Middle East and Africa, trading was mixed, while the Asia Pacific region delivered strong growth, led by South Korea.
Doximity Crushes The Rule Of 40 - Try Rule Of 58
I have a price target of $85 for Doximity by summer 2026. There is lots to be bullish about. Doximity's fundamentals are strong: zero debt, a large cash cushion, and robust free cash flow generation support my bullish outlook. Despite unimpressive 11% revenue growth guidance, DOCS surpasses the Rule of 40 with a Rule of 58, justifying a premium valuation.
Doximity (DOCS) Laps the Stock Market: Here's Why
Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.
Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?
DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?
DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.
DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?
DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.
Doximity: A Unique, Debt-Free Healthcare-Tech Platform, Initiate With 'Buy'
I rate Doximity a 'Buy' with a $62 fair value, citing its dominant network among U.S. healthcare professionals and robust growth trajectory. Doximity's strong pharma marketing business, workflow solutions, and AI-driven hiring tools underpin its competitive advantage and long-term expansion potential. The company's debt-free balance sheet, high free cash flow, and substantial share repurchases support its financial health and margin expansion outlook.
DOCS Boosts Client Retention via Workflow Integration and AI Tools
Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.
